Presenting data from a multicenter study performed in Italy, Dr E. Rigoni of the Università degli Studi di Pavia, Pavia, Italy, suggested that monitoring myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) in patients with acquired demyelinating syndromes (ADS) may not only have prognostic value but could also help guide disease management.